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The postoperative follow-up strategies for breast cancer patients
whether or not they are intensive usually include a relatively large
variety of radiological examinations (Winchester et al, 1979;
Horton, 1984; Pandya et al, 1985; Muss et al, 1988; Loomer et al,
1991; The GIVIO Investigators, 1994). For detecting bone
metastases, skeletal X-rays (Sx-ray), bone scanning (BS),
computed tomography (CT) and nuclear magnetic resonance
(NMR) may be performed. For chest involvement conventional
chest X-ray (CXR) and for liver metastases detection liver
echography (LE) and CT are useful.
LE depicts the presence of solid or cystic lesions in the liver.
There are no retrospective follow-up studies that have addressed
how often LE is the initial examination for detecting liver metas-
tases (ASCO, 1996). Two prospective studies that included LE in
an intensive surveillance programme failed to show a survival
benefit when compared with minimal surveillance based upon
history and physical examination (Rosselli Del Turco et al, 1994;
The GIVIO Investigators, 1994).
However, during the postoperative follow-up of breast cancer
patients conventional CXR and LE as well as other imaging
techniques, are usually performed for prognostic purposes because
of demands by the patients or for concomitant transient pathology
which needs to be differentiated from distant metastases of breast
cancer. Therefore it seems opportune to define the precise indica-
tions, sensitivity and specificity of these radiological exams in this
setting. Furthermore CXR and LE can give equivocal and false
positive results. Recently, the serum concentrations of tumour
markers have been used as a warning sign of distant metastases
(Neville et al, 1978; Schegel et al, 1981; Nicolini et al, 1989); the
combination of carcinoembryonic antigen (CEA), tissue poly-
peptide antigen (TPA) and breast cancer-associated antigen
115 D8/DF3 (CA15.3) has shown a sensitivity of 87% in the detec-
tion of breast cancer relapses with a 78% positive predictive value
(Nicolini et al, 1991a).
For many years we have performed a postoperative follow-up
programme for breast cancer patients which has included conven-
tional CXR, LE, and the CEA-TPA-CA15.3 tumour marker panel
(Nicolini et al, 1991a, 1997, 1999). In a previous retrospective
study we have shown that the CEA-TPA-CA15.3 tumour marker
panel can increase the accuracy of BS and Sx-ray in diagnosing
bony metastases by clarifying equivocal imaging results (Nicolini
et al, 1999). The aim of this study was to similarly assess the value
of serial determinations of the serum CEA-TPA-CA15.3 tumour
marker panel to identify amongst those breast cancer patients
with equivocal CXR or LE those affected with or at high risk of
developing thoracic or liver metastases respectively.
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Summary The aim of this retrospective study was to assess the value of a serum tumour marker panel in selecting from among the patients
with equivocal chest X-ray (CXR) or liver echography (LE) those with thoracic or liver metastases respectively. Between January 1984 and
December 1999, 467 (341 non-relapsed and 126 metastatic) breast cancer patients were followed-up postoperatively. Among the 126
metastatic patients 36 showed thoracic (19 patients) or liver (17 patients) metastases, alone or in conjunction with other organs as the first
evidence of distant spread. We focused on this series of 377 patients including 341 non-relapsed plus 36 with liver or thoracic metastases.
The patients were followed-up after mastectomy with serial determinations of a panel of CEA-TPA-CA15.3 tumour markers, bone
scintigraphy, CXR and LE. Up to December 1999, equivocal CXR occurred in 23 (6.1%) patients of whom 11 (47.8%) developed thoracic
metastases; 14 (3.7%) patients showed an equivocal LE of whom 5 developed liver metastases. In the 37 patients with equivocal CXR or
equivocal LE prolonged clinical and imaging follow-up over 41 ± 36 months (mean ± SD, range 3–163) was used to ascertain the presence or
absence of thoracic or liver metastases. In the 23 patients with equivocal CXR the negative and positive predictive values of the tumour
marker panel to predict thoracic metastases were 92% and 100% respectively. In the 14 patients with equivocal LE the negative and positive
predictive values of the tumour marker panel for prediction of liver metastases were 90% and 100% respectively. This study shows that in
breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value for selecting those patients at high risk of developing
clinically evident pulmonary or liver metastases from amongst those subjects with equivocal CXR or equivocal LE. © 2000 Cancer Research
Campaign http://www.bjcancer.com
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MATERIALS AND METHODS
Patients
Between January 1984 and December 1999, 467 (341 non-
relapsed and 126 metastatic) breast cancer patients were subjected
to postoperative follow-up. Among the 126 patients with
metastatic disease 36 showed thoracic (19 patients) or liver
(17 patients) metastases alone or concomitant with lesions in other
organs as the first site of distant spread. We focused on the series
of 377 patients including the 341 non-relapsed plus 36 with liver
or thoracic metastases. These 377 patients were 29 to 81 years old
and had axillary lymph-node involvement (N+) in 139 (36.8%). In
one patient, lung metastases were present at the time of mastec-
tomy. The postoperative follow-up visits were carried out every
6 or 4 months depending on whether they were N– or N+ at
pathological examination. ER- and PR-patients were allocated to
the shorter interval for follow-up. Initially the serum CEA-TPA-
CA15.3 panel determination, routine blood tests (ESR, glucose,
calcium, phosphorus, blood cell count, BUN, creatinine, GOT,
GPT, gamma-GT, bilirubin, alkaline phosphatase, immuno-
globulins), conventional CXR, BS, LE and a detailed history and
clinical examination were carried out to better define the post-
operative staging. Baseline Sx-ray was performed to distinguish
benign lesions due to inflammatory and/or degenerative disease
during the follow-up. Subsequently, at each postoperative follow-
up visit, every 4–6 months, the CEA-TPA-CA15.3 tumour marker
panel, the clinical and routine laboratory examinations were
performed in addition to the history; BS and LE were usually
performed every 24 months and CXR at more prolonged intervals
(mean value 42 months). In the 341 non-relapsed patients a total of
686 CXRs and 1364 LE were performed. CXRs were carried out at
56 ± 40 (mean ± SD) and LE at 25 ± 11 (mean ± SD) month
intervals. In the 35 relapsed patients the total number of CXRs
were 77 and LE were 93. CXRs were performed at 27 ± 29 (mean
± SD) and LE at 19 ± 9 (mean ± SD) month intervals. All the
377 studied patients were followed-up for at least 1 year and the
mean time was 98 ± 58 months.
Tumour markers
TPA was measured by IRMA (Sangtec Medical, Bromma,
Sweden) commercial kit. Serum levels initially >60 mU ml–1 and
subsequently >85 mU ml–1 were considered to be elevated.
Serum CA 15.3 concentrations were determined by IRMA (Cis
International) using a commercial kit and 32 mU ml–1 was taken as
the cut-off level. CEA was measured initially by Lepetit
Lysophase RIA (Milano, Italy) and subsequently by Sorin
Biomedica (Saluggia, Italy) commercial kits; both methods gave
superimposable results in appropriate comparative studies. Serum
levels >7 ng ml–1 were considered to be elevated. The within and
between assay coefficients of variation for CEA, TPA and CA15.3
were all less than 6% and 9%, respectively. When the TPA cut-off
value was 60 mU ml–1 the coefficients of variation increased to
10% and 15%, respectively, due to changes in the test procedure
using the same method. In our clinical study the serum tumour
marker level itself was much less important than their time-related
change. A dynamic evaluation of tumour markers was made and in
cases of a high tumour marker value a further blood sample was
drawn within a month of the previous elevated value. If the
remeasured tumour marker value had decreased to a normal level
the initial elevated value was considered to be an isolated elevated
value. The elevated tumour marker was considered to be progres-
sive when it was 30%, or more, higher in the sample which
followed the initial elevated value. Otherwise, two equally high
values were regarded to be a constant elevation. Only patients with
constant elevation or progressive increase of one or more tumour
markers, unexplained by any concomitant benign pathology or
history, were considered to be suspicious or indicative of tumour
relapse respectively (Nicolini et al, 1991b, 1997).
CXR and LE and the management of the patients with
equivocal finding
All conventional chest X-rays (CXRs) were carried out in 2
projections using the standard techniques. Liver ultrasound was
performed in our University Hospital using a 3.5 MHZ transducer
with 2 mm resolution. All CXRs and liver ultrasounds were read
by skilled radiologists and an official written report was given for
each examination.
Conventional CXR and LE were considered equivocal when in
the official report lesion(s) were described suspicious for relapse
but further examinations were requested to confirm their
metastatic origin. The lesions that were considered to be equivocal
by conventional CXR were clarified by CT or bronchoscopy and
cytologic study. In 2 patients repetitive conventional CXR were
soon carried out and prolonged clinical follow-up was used to
determine the nature of the equivocal imaging findings. The
lesions felt to be equivocal at LE were clarified by LE guided FNA
cytology when it was possible. In 1 patient CT and in another one
short-term repetition of LE together with prolonged clinical
follow-up was used to determine the nature of the equivocal
imaging finding.
In all these patients examined a prolonged follow-up (41 ± 36
months, mean ± SD; range 3–163) was used to finally clarify their
status whether they were or were not metastatic.
Statistical analysis
Probably positive tests were defined as (a) CXR and LE that were
pathological and (b) tumour marker assay panel with constant
elevation or progressive increase in one or more antigens,
unexplained by any concomitant transient or chronic benign
pathology. CXR and LE showing a picture of equivocal interpreta-
tion were also considered to be probably positive tests. A probably
positive test which was confirmed by monitoring to death or by the
development of a definite clinical-imaging course after the initial
result was defined as true positive. Probably negative tests were
defined as (a) negative CXR and LE and (b) tumour marker assay
panel with normal or isolated elevated value that persisted for
longer than 6 months after the first abnormal result. Probably
negative tests which were followed by at least 1 year of survival
without any clinical-imaging sign of relapse were then evaluated
as true negatives.
Sensitivity was defined as TP/(TP+FN)%, specificity as
TN/(TN+FP)%, accuracy as TN+TP/(TN+FN+TP+FP), positive
predictive value as TP/(TP+FP), negative predictive value as
TN/(TN+FN), where FP = false positive, FN = false negative,
TP = true positive, TN = true negative.
In patients with CXR or LE with equivocal interpretations the
exact Fisher’s test was applied to verify whether the tumourmarker panel had statistically significant power in distinguishing
true positives from true negatives.
RESULTS
General outcome and CXR and LE with equivocal
interpretation
Up to December 1999, 36 (7.7%) of the 467 patients manifested
thoracic (19 patients) or liver (17 patients) metastases as the first
site of relapse and in 35 of them these occurred during the post-
operative follow-up. 23 of these 35 patients were N+ and the
remaining 12 N–. Two patients of the 19 with thoracic relapse and
two other subjects of the 17 with metastatic liver involvement are
still alive. 89 (23.6%) of the 341 disease-free patients withdrew
from follow-up.
During the postoperative follow-up 37 (9.8%) of the 377
patients showed CXRs (23 patients) or LE (14 patients) with
equivocal interpretations. 12 of the 23 patients with equivocal
CXRs and 9 of the 14 with equivocal LE occurred in the 341 non-
relapsed patients. The remaining patients, 11 with equivocal CXRs
and 5 with equivocal LE were in the 19 and 17 patients with
thoracic and liver metastases respectively.
Non-relapsed patients: specificity of CEA-TPA-CA15.3
tumour marker panel
Table 1 shows the principal results of CEA-TPA-CA15.3 tumour
marker panel, CXR and LE in the 341 non-relapsed patients. In
these patients the overall specificity for excluding thoracic or liver
metastases of the tumour marker panel, CXR and LE were 100%,
96.5% and 99%, respectively. Importantly, 136 patients showed a
significantly elevated tumour marker panel concomitant with a
transient or chronic benign pathology. The tumour marker eleva-
tion was constant in 81 patients and/or progressive in 55 patients.
Diffuse fat infiltration of liver and/or diabetes, chronic liver
failure, hepatic cysts, chronic obstructive bronchopulmonary
disease, cholelithiasis, rheumatoid arthritis were the chronic
benign pathologies likely responsible for tumour marker constant
increase in 42, 9, 3, 2, 2 and 1 patient, respectively. Diffuse fat
infiltration of liver and/or diabetes and chronic liver failure also
were likely responsible for tumour marker constant and/or
progressive increase in 22 and 19 other patients, respectively.
Transient liver disorder (indicated by biochemical tests), acute
inflammation of joints, upper airways, bladder, lymphatic vessels
were the transient benign pathologies likely responsible for
tumour marker constant increase in 3, 2, 3, 1 and 1 patient, respec-
tively. Transient liver disorder, acute joint inflammation and acute
upper airways inflammation also were likely responsible for
tumour marker constant and/or progressive increase in 3, 2 and 1
other patient. Smoking was likely responsible for tumour marker
constant increase in 10 patients and for constant and/or progres-
sive increase in 8 other subjects. In 2 patients with tumour marker
constant increase no reason likely responsible for tumour marker
elevation was found. In most non-relapsed patients with signifi-
cant tumour marker panel increase the concomitant benign
pathology was ascertained by history, physical examination,
routine laboratory tests and instrumental investigations which
were performed consistent with the protocol. In few of them a well
documented history requested by the general practitioner also was
available. Therefore no test in addition to those of the protocol was
carried out to ascertain the concomitant benign pathology.
12 (3.5%) and 9 (2.6%) of the 341 non-relapsed patients had
CXR and LE with equivocal interpretation, respectively. In 18
(86%) of these 21 non-relapsed patients 11 with equivocal CXR
and 7 with equivocal LE, CEA-TPA-CA15.3 tumour marker panel
was negative. One (8%) of the 12 non-relapsed patients with
equivocal CXR showed concomitant constant increase in serum
TPA level. This patient was affected by diffuse fat infiltration of
liver and diabetes. Two (22%) of the 9 non-relapsed patients with
equivocal LE showed concomitant constant increase in serum TPA
levels. One of these two patients was affected by diffuse fat infil-
tration of the liver and diabetes. The other was affected by diffuse
fat infiltration of the liver and chronic obstructive broncho-
pulmonary disease. Therefore none of these 3 patients was
considered suspected for relapse. In these 21 patients aged 37–75
1414 A Nicolini et al
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Table 1 False positive results for the diagnosis of thoracic or liver metastases in 341 non relapsed breast cancer patients
Test type Tn Result Probably positive test (n) Test specificity (%)
Tumour marker panel 5682 136+ 0a 100
Chest X-ray 686 12e 12 96.5
Liver echography 1364 9e 9 99
Tn = total number of tests; Result = number of patients with (e) equivocal initial imaging result or (+) significantly elevated tumour marker panel; ain all 136
patients a transient or chronic benign pathology occurred concomitant with significant elevation (constant and/or progressive) in one or more tumour markers.
Table 2 False negative results in 19 breast cancer patients with thoracic metastases and in 17 with liver metastases
Test type Tn Result Probably negative test (n) Test sensitivity (%)
Tumour marker panel 604 3– 2a 94.5
Chest X-ray 79 11e 1 95b
1 negative
Liver echography 94 5e 2 88b
2 negative
Tn = total number of tests; Result = number of patients with (e) equivocal initial imaging result or (–) normal or not significantly elevated tumour marker panel;
ain 2 patients the tumour marker panel remained not significantly elevated for longer than 6 months after the first abnormal results; bpatients first suspected due
to abnormal CEA-TPA-CA15.3 tumour marker panel were included.years (53.2 ± 9.5, mean ± SD), 7 (33%) were premenopausal and
5 (24%) were N+ and thoracic and liver metastases were not
confirmed during a mean clinical-imaging follow-up over more
than 53 months (range 12–163).
Relapsed patients: sensitivity of CEA-TPA-CA15.3
tumour marker panel
Table 2 shows the principal results of the CEA-TPA-CA15.3
tumour marker panel, CXR and LE in the 36 patients with thoracic
(19 patients) or liver metastases (17 patients). In these relapsed
patients the overall sensitivity for suspecting thoracic or liver
metastases of the tumour marker panel, CXR and LE were 94.5%,
95% and 88%, respectively. Specifically, in 2 patients with
thoracic metastases the tumour marker panel remained normal or
not significantly elevated for longer than 6 months after the first
abnormal result. In a third case with liver metastases a constant
increase in serum TPA values occurred 6 months after the first
abnormal finding.
In 17 (89%) of the 19 patients with thoracic metastases constant
elevation or progressive increase in one or more tumour markers in
the panel which was not explained by another concomitant chronic
or transient pathology, was the first sign of relapse alone or
together with a pathologic (1 patient) (5.2%) or equivocal
(5 patients) (26%) CXR. In 7 (63.6%) of the 11 patients with an
equivocal CXR thoracic metastases were confirmed by thoracic
CT and in 2 others by cytologic study of a sample taken during
bronchoscopy. In the 2 remaining cases the progression of the
lesions on frequently performed CXRs allowed the metastatic
origin of thoracic involvement to be ascertained.
In 16 (94%) of the 17 patients with liver metastases a constant
elevation or progressive increase in one or more tumour markers in
the panel which could not be explained by an alternative concomi-
tant chronic or transient benign pathology was the first sign of
relapse alone (13 patients) or concomitant with equivocal
(2 patients) (11.7%) or pathologic (1 patient) (5.9%) LE. In
3 (60%) of the 5 patients with equivocal LE liver metastases were
confirmed by LE-guided cytology. In another patient liver
metastases were confirmed by liver CT. In the remaining patient
the repeated LE finally allowed the metastatic origin of liver
involvement to be confirmed.
The role of tumour markers in confirming or excluding
thoracic or liver metastases in the patients with
equivocal CXR or equivocal LE
Table 3 shows that among the 23 patients with equivocal conven-
tional CXR only one of the 11 relapsed patients had a normal
tumour marker panel or a panel which was not significantly
elevated, while all the 12 non-relapsed patients showed a normal
(11) or significantly elevated (1) tumour marker panel explained
by concomitant benign pathology (P = 0.00001, exact Fisher’s
test). Therefore, the sensitivity and specificity of the tumour
marker panel for detection of thoracic metastases in these patients
was 91% and 100%, respectively. Similarly, Table 4 shows that
among the 14 patients with equivocal LE only one of the 5
relapsed patients had a normal tumour marker panel or a panel
which was not significantly elevated while all the 9 non-relapsed
patients had a normal (7) tumour marker panel or a panel which
was significantly elevated (2) and explained by concomitant
benign pathology (P = 0.005, exact Fisher’s test). Therefore sensi-
tivity and specificity of the tumour marker panel for detection of
liver metastases was 80% and 100%, respectively.
The positive and negative predictive value of the CEA-
TPA-CA15.3 tumour marker panel in the 23 patients with
equivocal CXR was 100% and 92%, respectively.
The positive and negative predictive value of the CEA-
TPA-CA15.3 tumour marker panel in the 14 patients with
equivocal LE was 100% and 90%, respectively.
DISCUSSION
In breast cancer patients who are or are not submitted to a delib-
erate postoperative follow-up CXR and LE can be utilized to
distinguish secondary thoracic or liver involvement from an alter-
native pathology. To this purpose conventional CXR and LE
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Table 3 Tumour marker panel in 23 patients with an equivocal chest X-ray
Non relapsed Patients with
Exam patients (n = 341) thoracic metastases (n = 19)
Equivocal chest x-ray (n)1 21 1
Tumour marker panel + (n)0 a 10a
Tumour marker panel – (n)1 2 a 1a
Tumour marker panel specificity 100% –
Tumour marker panel sensitivity – 91%
(+) significantly elevated; (–) normal or not significantly elevated tumour marker panel; aP = 0.00001, exact Fisher’s test.
Table 4 Tumour marker panel in 14 patients with equivocal liver echography
Non-relapsed Patients with
Exam patients (n = 391) liver metastases (n = 17)
Equivocal liver echography (n) 9 5
Tumour marker panel + (n) 0a 4a
Tumour marker panel – (n) 9a 1a
Tumour marker panel specificity 100% –
Tumour marker panel sensitivity – 80%
(+) significantly elevated; (–) normal or not significantly elevated tumour marker panel; aP = 0.005, exact Fisher’s test.1416 A Nicolini et al
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proved to be highly specific examinations (Winchester et al, 1979;
Logager et al, 1990; Kruskal and Kane, 1992; The GIVIO
Investigators, 1994) but some imaging findings occur which are
subjected to equivocal interpretation. Equivocal CXR and LE
imaging findings may also occur in the presence of metastatic
lesions at the limit of the detectability of these radiological exami-
nations. It is well known that CXR findings can be difficult to
interpret to definitely diagnose distant metastases from breast
cancer in presence of a single lesion of any size or when multiple
nodules show irregular and ill-defined margins. Also the origin of
disseminated miliary nodules and of carcinomatous lymphangitis
can be difficult to interpret (Fargnoli et al, 1999). With regard to
LE the commonest patterns which are difficult to interpret are the
following: a) widely ‘irregular’ liver with ‘skip areas’; this picture
often occurs in patients previously treated with chemotherapy;
b) ‘regular’ liver with single or multiple echogenic areas (Kruskal
and Kane, 1992).
When equivocal CXR or LE occur, repetition of the examina-
tion in a short time is a simple but not always effective way to
solve the problem. Furthermore it entails a delay in starting
therapy when the lesions are of metastatic origin. Thoracic or liver
CT, or NMR, can usually determine the nature of the non-specific
lesions detected by CXR or LE; however they are expensive and
time-consuming examinations. In a few instances invasive proce-
dures such as bronchoscopy, LE or CT guided fine needle aspira-
tion (FNA) are necessary to define the nature of the lesions which
are equivocal on CXR or LE. Therefore there is a need for simple
means to better select patients with equivocal LE or CT for more
expensive examinations or invasive procedures.
In this study of breast cancer patients they were monitored post-
operatively by means of clinical examinations, routine laboratory
tests, CEA-TPA-CA15.3 tumour marker panel and imaging tech-
niques including conventional CXR and LE. Clinical examination,
routine laboratory tests and CEA-TPA-CA15.3 tumour marker
panel are a tool more easily repeatable, cheaper, more harmless
and better accepted by the patients than instrumental examina-
tions. The high accuracy of the tumour marker panel in our study,
particularly diagnostic sensitivity in the detection of distant metas-
tases, may partly be due to the high frequency of test repetition
compared to that of CXR and LE. However previous studies eval-
uating the accuracy of intensive follow-up with instrumental
examinations for the same purpose including CXR and/or LE did
not show accuracy values comparable to those obtained by the
tumour marker panel we used (Ciatto and Herd-Smith, 1983;
Logager et al, 1990; Schapira and Urban, 1991; The GIVIO
Investigators, 1994). The accuracy and negative predictive value
of the CEA-TPA-CA15.3 tumour marker panel which we previ-
ously reported for diagnosis of bone metastases in patients with
equivocal BS (Nicolini et al, 1999) were similar to those we found
in this study for diagnosis of chest or liver metastases in patients
with equivocal CXR or equivocal LE. However in the previous
study on equivocal BS the tumour marker panel showed a lower
positive predictive value than in the present study on equivocal
CXR and LE (75% vs 100%). It is likely that the more frequent
occurrence of equivocal BS in the non-relapsed patients was
because of the well known low specificity of this examination
(Fogelman, 1991). Equivocal CXR or equivocal LE occur much
more rarely in non-relapsed patients.
These data clearly point out that CEA-TPA-CA15.3 tumour
marker panel is an accurate tool for selecting patients with
equivocal CXR or LE and that only those patients with a concomi-
tant significantly elevated tumour marker panel can be further
studied with CT or NMR and/or undergo invasive procedures to
further define the nature of lesions. This advantage is limited by
the relatively low incidence of equivocal CXR or LE. These results
occurred however in 16/36 of our patients with initial thoracic or
liver metastases and in 21/341 of the non-relapsed women. The use
of tumour markers in the latter patient group (non-relapsed with
equivocal CXR or LE) shows the potential advantage for avoiding
unnecessary antitumour therapy were such equivocal imaging
finding to be interpreted as positive. In this study the CEA-
TPA-CA15.3 tumour marker panel alone or together with CXR or
LE was the first sign of relapse in 89% and 94% of patients with
thoracic and liver metastases respectively. In a recent review of our
updated data we confirmed that in some patients the ‘early’ treat-
ment of breast cancer relapses (i.e. when tumour markers are
elevated and radiological examinations are not yet positive)
significantly prolongs disease-free and overall survival (Nicolini
and Carpi, 2000). These important benefits thus improve the 
cost-effectiveness of postoperative monitoring of the breast cancer
patient by using the CEA-TPA-CA15.3 tumour marker panel.
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